Israeli Treatment Found to be Effective for Fibromyalgia Patients

Fibromyalgia is an unexplained pain disease and its treatment is often ineffective. An Israeli study that examined hundreds of patients found that 81% of patients resistant to treatment reported a significant improvement in their condition after six months in the treatment of medical cannabis.

An Israeli study that tracked hundreds of patients with fibromyalgia during a half-year of treatment with medical cannabis found that the treatment significantly reduced the symptoms of the patients.

The treatment, according to a study published in the Journal of Clinical Medicine last month, reduced the chronic pain of patients from an average level of 9 to 5, and reduced the use of addictive drugs to relieve pain in nearly a quarter of patients.

Fibromyalgia is a chronic pain disease accompanied by fatigue and sensitivity. The disease, which is more common in women, causes widespread pain in the musculoskeletal system and affects 3-4 percent of the population. The causes of the disease are unknown and the effectiveness of treatment is very limited. Fibromyalgia is diagnosed by a pain response by pressing at least 11 points in the body out of the 18 susceptibility of patients.

“We have followed 367 patients for half a year of medical cannabis treatment at Tikkun Olam,” says Dr. Yiftah Sagi, a physician at the Soroka Medical Center’s unit of rheumatology and a researcher at the hospital’s clinical research center. “This is the largest study ever published in the treatment of cannabis Medical treatment in patients with fibromyalgia. ”

The study found that more than 81% of the patients reported a significant improvement in their condition at the end of the year. The chronic pain level reported by participants decreased from 9 on a scale of 0 to 10 to a level of 5. 73% of the patients also reported improvement in sleep disorders, one of the common symptoms of the disease.

“Cannabis is a last resort for patients with fibromyalgia,” said Dr. Sagi, who, together with Prof. Victor Novak, Prof. Mahmud Abu Shakra and Leahy Bar-Lev Shaleider, Director of Research in Tikkun Olam, conducted the study.

“Patients reported a significant improvement in their physical condition and quality of life,” adds Dr. Sagi. “More than 22 percent of patients reported reductions or discontinuations of opioid analgesics. More than 20% reduced the dosage of benzodiazepines for insomnia.

“The awareness of the harmful effects of addictive drugs is increasing in the world,” said the report, which was published in the Journal of Clinical Psychology.

“There is still no data on the long-term effects of cannabis and the study was not a control group, but the results point to positive indications encouraging further research in the field,” Sagi says.